{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:56:41Z","timestamp":1759341401731},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,2,25]],"date-time":"2005-02-25T00:00:00Z","timestamp":1109289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2002<\/jats:bold> To perform a clinical audit of all patients diagnosed with inflammatory myopathy in the North Canterbury region.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> A retrospective case note audit of patients with a discharge diagnosis of inflammatory myopathy from June 1989 to June 2001 was performed. The audit was based at Christchurch Hospital, New Zealand, which services a population of 430\u2003000.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Of 77 case notes reviewed, 44 patients were identified who were considered to fulfil clinical criteria for inflammatory myopathy. There was a female preponderance (80% female, 20% male). Diagnostic categories in descending order of frequency included: dermatomyositis (41%), polymyositis (39%), inclusion body myositis (IBM) (14%) and overlap syndromes (6%). Malignancy\u2010associated myositis occurred in 20% overall (dermatomyositis 11%, polymyositis 9%). Delays in diagnosis and late age at presentation (average 72\u2003years) were seen in the IBM group. Proximal limb weakness was common, but not universal at presentation (80%). A muscle biopsy was performed in all patients and electromyography in 82%. All were treated with high dose prednisone (0.5\u20131\u2003mg\/kg) of whom 29% were maintained on prednisone alone. Immunosuppressives\/immunomodulators used included: azathioprine (58%), methotrexate (31%), intravenous immunoglobulin (13%), chlorambucil (13%), and cyclophosphamide (9%). Thirteen patients (42%) required more than one agent, with three trialling five agents. There were 59 relapses in 20 patients (45%), with mean time to first relapse of 7.8\u2003months. At audit completion, 33% had deceased with malignancy and respiratory failure the main causes.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Inflammatory myopathy is a challenging condition in both diagnosis and management. Our audit has shown delays in the diagnosis of IBM, a relatively high incidence of malignancy and a notable risk of relapse and mortality. (Intern Med J 2005; 35: 170\u2013173)<\/jats:p>","DOI":"10.1111\/j.1445-5994.2004.00764.x","type":"journal-article","created":{"date-parts":[[2005,2,25]],"date-time":"2005-02-25T20:10:44Z","timestamp":1109362244000},"page":"170-173","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Adult\u2010onset inflammatory myopathy: North Canterbury experience 1989\u20132001"],"prefix":"10.1111","volume":"35","author":[{"given":"S. J.","family":"Lynn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Sawyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. W.","family":"Moller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. T.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1335","volume-title":"Myology","author":"Engel AG","year":"1994"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(02)00021-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252107"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(02)00021-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10053"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(02)00030-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868438"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-12-200106190-00008"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03540-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260602"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.7.969"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.7.885"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<651::AID-MUS1>3.0.CO;2-7"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200010000-00001"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.6_Suppl_5.S37"},{"key":"e_1_2_6_20_2","first-page":"263","article-title":"Long\u2010term prognosis of 69 patients with dermatomyositis or polymyositis","volume":"14","author":"Maugars YM","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.1.22"},{"key":"e_1_2_6_22_2","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short\u2010term and long\u2010term outcome, and predictive factors of prognosis","volume":"28","author":"Marie I","year":"2001","journal-title":"J\u2003Rheumatol"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2004.00764.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2004.00764.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:49:24Z","timestamp":1696880964000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2004.00764.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,25]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1445-5994.2004.00764.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2004.00764.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,25]]},"assertion":[{"value":"2005-02-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}